Q2 2024 revenues of $800.7 million, up 17.4% year-over-year (yoy); organic revenue up 7.4% yoy; CER revenue up 18.5% yoy Q2 2024 GAAP EPS $0.05; non-GAAP EPS $0.52, up 4.0% yoy Bruker increases FY 2024 revenue guidance to $3.38-$3.44 billion, now including the NanoString business; implies revenue growth of 14% to 16%, and organic revenue... Read more
WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2024. Second Quarter 2024 Highlights Second quarter revenue was $10.54 billion. Second quarter GAAP diluted earnings per share (EPS) increased 15% to $4.04. Second quarter adjusted EPS increased... Read more
WASHINGTON, July 23, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the quarter ended June 28, 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Second Quarter 2024 Results Net earnings were $907 million, or $1.22 per diluted common share and non-GAAP adjusted diluted net... Read more
Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs. Integrated AI and microscopy expected to lead to better understanding of tumor structures and treatment strategies. New technology... Read more
Subsequent Offering Period Scheduled to Expire at 5:00 p.m., New York Time, on July 16, 2024 WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has completed its acquisition of Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading provider of next-generation proteomics... Read more
Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics WASHINGTON, June 19, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (“Danaher” or the “Company”), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr.... Read more
Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers using highly sensitive technology from Beckman Coulter Diagnostics. This approach could potentially be adapted for diagnosis of other... Read more
Q1 2024 revenues of $721.7 million, up 5.3% year-over-year (yoy); organic revenue up 1.6% yoy, and constant-exchange rate (CER) revenue up 5.5% yoy Q1 2024 GAAP EPS of $0.35; non-GAAP EPS of $0.53 Updated FY 2024 guidance: Revenue $3.29 to $3.35 billion, up $60 million from prior guidance, implying reported growth of 11% to 13%... Read more
WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2024. First Quarter 2024 Highlights Continued to strengthen our industry-leading commercial engine and deepen our trusted partner status with customers to accelerate innovation and enhance productivity with the... Read more
WASHINGTON, April 23, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the quarter ended March 29, 2024. All results in this release reflect only continuing operations unless otherwise noted. Key First Quarter 2024 Results Net earnings were $1.1 billion, or $1.45 per diluted common share and non-GAAP adjusted diluted net... Read more